< Back to previous page
Researcher
Pieter Gillard
- Disciplines:Endocrinology and metabolic diseases
Affiliations
- Clinical and Experimental Endocrinology (Division)
Member
From1 Oct 2009 → Today
Projects
1 - 10 of 11
- Assessing novel technologies and glucometrics to improve glucose control and quality of life of people with type 1 diabetesFrom1 Oct 2023 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Technological improvements in the management of type 1 diabetesFrom1 Sep 2023 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- The road to personalized management of type 1 diabetes with a focus on closed-loop devicesFrom2 Aug 2021 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- The use of novel technologies with a focus on the individual needs of people living with type 1 diabetesFrom1 Oct 2020 → 30 Sep 2021Funding: BOF - postdoctoral mandates
- Closed-loop insulin delivery in pregnant women with type 1 diabetes (the CRISTAL study)From1 Oct 2020 → TodayFunding: FWO Strategic Basic Research Grant, BOF - doctoral mandates
- Exploring the use of continuous glucose monitoring to improve glycemic control and quality of life in type 1 diabetesFrom1 Jan 2019 → 31 Mar 2023Funding: Own budget, for example: patrimony, inscription fees, gifts
- Histology: a vital tool for endocrine and metabolic researchFrom1 Oct 2016 → 30 Sep 2018Funding: Fund Recuperation Fiscal Exemption
- Identification of patient-specific parameters for bolus calculators in type 1 diabetic patientsFrom15 Aug 2016 → 31 Dec 2020Funding: FWO Strategic Basic Research Grant
- Robust identification of patient-specific parameters for bolus calculators in type 1 diabetic patientsFrom1 Oct 2015 → 30 Sep 2017Funding: IOF - Industrial Research Fund
- The beta-cell and the immune system in type 1 diabetes: partners in crime - developing new therapies in type 1 diabetes through better understanding of beta-cell behaviour and use of novel immunomodulators.From1 Oct 2013 → 30 Sep 2018Funding: BOF - Concerted Research Project from 1994
Publications
11 - 20 of 116
- SARS-CoV-2 vaccine antibody response and breakthrough infections in transplant recipients(2023)
Authors: Kris Bogaerts, Pieter Vermeersch, Katrien Lagrou, Geert Molenberghs, Filip Rega, Laurens Ceulemans, Dirk Van Raemdonck, Ina Jochmans, Diethard Monbaliu, Jacques Pirenne, et al.
- Sustained Impact of Intermittently Scanned Continuous Glucose Monitoring on Treatment Satisfaction and Severe Hypoglycemia in Adults with Type 1 Diabetes (FUTURE): An Analysis in People with Normal and Impaired Awareness of Hypoglycemia(2023)
Authors: Chantal Mathieu, Pieter Gillard
Pages: 231 - 241 - Exploring the use of continuous glucose monitoring to improve glycemic control and quality of life in type 1 diabetes(2023)
Authors: Pieter Gillard, Chantal Mathieu
- CTLA4, SH2B3, and CLEC16A diversely affect the progression of early islet autoimmunity in relatives of Type 1 diabetes patients(2023)
Authors: Pieter Gillard
Pages: 224 - 232 - Closed-loop insulin delivery in pregnant women with type 1 diabetes (CRISTAL): a multicentre randomized controlled trial - study protocol(2023)
Authors: Kaat Beunen, Annouschka Laenen, Pieter Gillard, Chantal Mathieu, Katrien Fouzia Benhalima
- Effect of switching from intermittently scanned to real-time continuous glucose monitoring in adults with type 1 diabetes: 24-month results from the randomised ALERTT1 trial(2023)
Authors: Steffen Fieuws, Chantal Mathieu, Pieter Gillard
Pages: 96 - 108 - Effect of nationwide reimbursement of real-time continuous glucose monitoring on HbA1c, hypoglycemia and quality of life in a pediatric type 1 diabetes population: The RESCUE-pediatrics study(2022)
Authors: Kristina Casteels, Pieter Gillard
- The Impact of Baseline User Characteristics on the Benefits of Real-Time Versus Intermittently Scanned Continuous Glucose Monitoring in Adults With Type 1 Diabetes: Moderator Analyses of the ALERTT1 Trial.(2022)
Authors: Sara Charleer, Steffen Fieuws, Chantal Mathieu, Pieter Gillard
Pages: 1932296822 - Ladarixin, an inhibitor of the interleukin-8 receptors CXCR1 and CXCR2, in new-onset type 1 diabetes: A multicentre, randomized, double-blind, placebo-controlled trial(2022)
Authors: Pieter Gillard
Pages: 1840 - 1849 - Diabetic Ketoacidosis After Sodium-Glucose Cotransporter Inhibitor Initiation Under Advanced Hybrid Closed-Loop Therapy in Type 1 Diabetes(2022)
Authors: Chantal Mathieu, Pieter Gillard
Pages: 516 - 519